Early initiation of moderate-intensity aerobic exercise during aromatase inhibitor use reduced pain and prevented pain increases among postmenopausal women with breast cancer. Early initiation of ...

Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

Optimal lead follicle size of 19 to 23 mm was associated with improved clinical pregnancy rates among patients undergoing IUI.